Novartis buys remaining rights to GSK treatment in deal up to $1 bln
ZURICH, Aug 21 (Reuters) - Swiss drugmaker Novartis said on Friday it had agreed to buy all remaining rights to Ofatumumab, which is being developed for relapsing remitting multiple sclerosis and other autoimmune indications, from Britain's GlaxoSmithKline. Basel-based Novartis will make a
